The patient sample was tested for tpsa using a "clia" test method and the result was 0.69 ng/ml.The sample was provided for investigation, where it was tested on an e601 analyzer and an e602 analyzer.When tested on an e601 analyzer on (b)(6) 2017, the sample had a tpsa result of 0.601 ng/ml and an fsa result of 0.660 ng/ml.The sample was repeated on the e601 analyzer on (b)(6) 2017, resulting with a tpsa value of 0.600 ng/ml and a fpsa value of 0.649 ng/ml.When tested on the e602 analyzer on (b)(6) 2017, the sample had a tpsa result of 0.614 ng/ml and a fpsa result of 0.643 ng/ml.The sample was also tested using an outsourced "psa-act"/"acs-cpsa free psa" test method on the advia centaur analyzer, resulting with a value of 0.2 ng/ml.Preliminary investigations determined the issue may be related to the very low psa concentration of the sample.A non-specific reaction was not observed.The serial numbers of the e601 analyzer and e602 analyzer used for investigations were asked for, but not provided.The reagent lot number used on the investigation e601 analyzer was tpsa reagent lot number 135984, with an expiration date of 05/31/2017.The reagent lot number used on the investigation e602 analyzer was tpsa reagent lot number 135984, with an expiration date of 05/31/2017.
|